Renier Brentjens, MD, PhD, has spent most of his career pioneering research into the development and use of CAR T-cell therapies in the hopes of finding innovative and effective treatments for cancer. But as the Chair of Medicine and Deputy Director of Roswell Park Comprehensive Cancer Center, his eyes are on what comes next.

Here he provides an overview of clinical trials currently in development at Roswell Park and anticipated to open within the next six to 12 months for osteosarcoma, small-cell lung cancer and ovarian cancer, in addition to some new trials for liquid tumors.

“CAR T-cell therapy is a technology that’s still very much in its infancy. There are only a handful of academic institutions and cancer centers that have the capacity to move this technology from the laboratory to the patient’s bedside,” he says. “Roswell Park has now become one of those premiere centers where this technology is available.”

Related Presenters

Renier Brentjens, MD, PhD

Deputy Director
Professor of Oncology
Chair, Department of Medicine
Department of Immunology
The Katherine Anne Gioia Endowed Chair in Cancer Medicine

Dr. Brentjens obtained an MD/PhD (microbiology) from SUNY Buffalo, completed a residency in medicine at Yale New Haven Hospital, and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center (MSKCC). As a medical oncology ...

View full profile